Half-year report · HY
3341.TEDINET S100X3D6
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥191.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥360.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥175.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥423m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥4.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.9bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥772m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.0bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥762m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥210.3bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥197.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥204.1bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥150.5bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥138.0bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥59.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.5bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥16.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥5.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥9.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥4.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥37.06 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.44 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥6.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥6.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥3.4bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥172.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥172.0bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥7.3bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9m |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥388m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥20.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥14.0bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥122m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥198.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥191.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥7.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.2bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.5bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥122m |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥766m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.6bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥182.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥175.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 529
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 5840000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.1948 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 612100 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0204 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 233200 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0078 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 198370 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0066 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 140769 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0047 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 111462 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0037 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 104235 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0035 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 84000 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0028 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 56200 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0019 | |
| Number of shares held | InterimInstant | 29209884 | |
| Shareholding ratio | InterimInstant | 0.9742 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1062100 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 29957100 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 299571 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 28800 | |
| Number of shares issued shares voting rights | InterimInstant | 31048000 | |
| Number of voting rights issued shares voting rights | InterimInstant | 299571 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 1062100 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 1062100 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0342 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 1062100 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 1062100 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0342 | |
| Number of male directors and other officers | FilingDateInstant | 8 | |
| Number of female directors and other officers | FilingDateInstant | 2 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.20 | |
| Cash and deposits | Prior1YearInstant | 27463000000 | JPY |
| Cash and deposits | InterimInstant | 16494000000 | JPY |
| Notes receivable trade | Prior1YearInstant | 8000000 | JPY |
| Notes receivable trade | InterimInstant | － | JPY |
| Trade receivables and contract asset ca | Prior1YearInstant | 23167000000 | JPY |
| Trade receivables and contract asset ca | InterimInstant | 40974000000 | JPY |
| Electronically recorded monetary claims operating ca | Prior1YearInstant | 360000000 | JPY |
| Electronically recorded monetary claims operating ca | InterimInstant | 388000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 29507000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |